Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist, a class of medications primarily used in the management of type 2 diabetes mellitus. It is available as a subcutaneous injection under brand names such as Byetta (an immediate-release formulation, typically administered twice daily) and Bydureon (an extended-release formulation, administered once weekly). While its primary indication is for improving glycemic control, exenatide also has significant effects on body weight, often leading to weight loss. It is not indicated for type 1 diabetes or for diabetic ketoacidosis. As a non-insulin injectable medication, its use is typically considered when metformin and/or other oral antihyperglycemic agents have not achieved adequate glycemic control.
Exenatide was one of the first GLP-1 receptor agonists introduced to the market. Its structure is a synthetic version of exendin-4, a hormone originally isolated from the saliva of the Gila monster (Heloderma suspectum). This evolutionary origin highlights its unique biological properties that mimic naturally occurring incretin hormones in humans.
Deep dive
Tap a section to expand.
Known interactions
Category rule: glp1 × supplement
Note
GLP-1 medications slow stomach emptying, changing how/when oral supplements absorb; rapid weight loss raises the importance of protein and micronutrients.
Time oral supplements when nausea is lowest; prioritize protein and micronutrients; discuss with your provider.
Compound-pair rule
Caution
Combining a GLP-1 with rapid insulin increases hypoglycemia risk.
Reduce mealtime insulin at GLP-1 initiation; monitor glucose closely.
Compound-pair rule
Caution
GLP-1 plus basal insulin increases hypoglycemia risk.
Reduce basal insulin dose 10–20% at GLP-1 initiation and titrate.
Frequently asked
Sources referenced
["U.S. Food and Drug Administration (FDA) label", "National Institutes of Health (NIH) - Office of Dietary Supplements (ODS)", "MedlinePlus (National Library of Medicine)", "PubChem (National Library of Medicine)", "Mayo Clinic", "European Medicines Agency (EMA) - Summary of Product Characteristics (SmPC)", "Cochrane Library", "DrugBank"]
Stackwise compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician.
Related compounds
Others in the glp1 category or studied for the same goals.
